// App-Quantinova.ai

595 : Differential ligand binding distinguishes therapeutic from pathologic Aryl Hydrocarbon Receptor (AhR) modulating agents: Implications for inflammatory skin disease

Researchers

Presenter

  • S. Smith

Principal Investigators

  • K. McHale

  • K. Creech

  • D. Rickard

  • C. Jayawickreme

  • D. Wu

  • F. Rastinejad

  • D. Rubenstein

Medical Centers

  • GlaxoSmithKline, Upper Providence, PA, United States.

  • Dermavant Sciences Inc, Durham, North Carolina, United States

  • University of Oxford, Oxford, United Kingdom

Locations

  • United States

  • China

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

  • Autoimmune (AI)

Disease

  • Atopic Dermatitis

  • Psoriasis

Biomarkers

  • N/A

Drug/Treatment

  • WBI-1001

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved